Mar 6 |
When Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?
|
Mar 5 |
2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call Transcript
|
Mar 5 |
2seventy bio GAAP EPS of -$1.11 misses by $0.06, revenue of $10.68M misses by $4.51M
|
Mar 5 |
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Progress
|
Mar 5 |
Earnings Scheduled For March 5, 2024
|
Mar 1 |
2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor Conferences
|
Feb 5 |
2seventy bio to Participate in Upcoming Investor Conferences
|
Feb 5 |
Bristol Myers, 2seventy bio to face FDA panel in March for Abecma decision
|
Feb 5 |
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
|
Jan 31 |
Leerink ups 2seventy to outperform, cites attractiveness as takeover target
|